Coronary artery disease: Pathogenesis and acute coronary syndromes

Mount Sinai Journal of Medicine

Volumn 68, Issue 3, 2001, Pages 167-181

  Worthley, Stephen G ^a   Osende, Julio I ^a   Helft, Gérard ^a   Badimon, Juan J ^a   Fuster, Valentin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; Atherogenesis; Atherosclerosis; Collateral circulation; Hemodynamics; Plaque disruption; Plaque formation; Platelet aggregation; Platelets; Q wave myocardial infarction; Rheology; Risk factors; Thrombogenicity; Thrombosis

Indexed keywords

CHEMOKINE; LIPOPROTEIN;

BLOOD; BLOOD RHEOLOGY; CLASSIFICATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; THROMBOSIS; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

CHEMOKINES; CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; ENDOTHELIUM, VASCULAR; HEMORHEOLOGY; HUMANS; LIPOPROTEINS; RISK FACTORS; THROMBOSIS; VASOCONSTRICTION;

EID: 0035347550     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (161)

1. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89:2462-2478.
2. Davies PF. Flow-mediated endothelial mechanotransduction. Physiol Rev 1995; 75:519-560.
3. Gimbrone MA, Jr. Vascular endothelium, hemodynamic forces, and atherogenesis. Am J Pathol 1999; 155:1-5.
4. Ku DN, Giddens DP, Zarins CK, Glagov S. Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis 1985; 5:293-302.
5. Ross R, Bowen-Pope DF, Raines EW. Platelet-derived growth factor and its role in health and disease. Philos Trans R Soc Lond B Biol Sci 1990; 327:155-169.
6. Grabowski EF, Jaffe EA, Weksler BB. Prostacyclin production by cultured endothelial cell monolayers exposed to step increases in shear stress. J Lab Clin Med 1985; 105:36-43.
7. Vanhoutte PM. Endothelium and control of vascular function. State of the art lecture. Hypertension 1989; 13:658-667.
8. Busse R, Pohl U, Luckhoff A. Mechanisms controlling the production of endothelial autacoids. Z Kardiol 1989; 78:64-69.
9. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986; 250:H1145-1149.
10. Malek AM, Jackman R, Rosenberg RD, Izumo S. Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Circ Res 1994; 74:852-860.
11. Takada Y, Shinkai F, Kondo S, et al. Fluid shear stress increases the expression of thrombomodulin by cultured human endothelial cells. Biochem Biophys Res Commun 1994; 205:1345-1352.
12. Kawai Y, Matsumoto Y, Ikeda Y, Watanabe K. Regulation of antithrombogenicity in endothelium by hemodynamic forces. Rinsho Byori 1997; 45:315-320.
13. Lin MC, Almus-Jacobs F, Chen HH, et al. Shear stress induction of the tissue factor gene. J Clin Invest 1997; 99:737-744.
14. Simionescu N, Vasile E, Lupu F, et al. Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol 1986; 123:109-125.
15. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997; 100:2680-2690.
16. Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990; 344:254-257.
17. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993; 178:449-460.
18. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in atherosclerosis: Studies of osteopetrotic mice. Am J Pathol 1997; 150:1687-1699.
19. de Villiers WJ, Smith JD, Miyata M, et al. Macrophage phenotype in mice deficient in both macrophage-colony-stimulating factor (op) and apolipoprotein E. Arterioscler Thromb Vasc Biol 1998; 18:631-640.
20. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
21. Libby P, Ross R. Cytokines and growth regulatory molecules. Philadelphia: Lippincott-Raven; 1996.
22. Celentano DC, Frishman WH. Matrix metalloproteinases and coronary artery disease: A novel therapeutic target. J Clin Pharmacol 1997; 37:991-1000.
23. Pauly RR, Passaniti A, Bilato C, et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 1994; 75:41-54.
24. de Boer OJ, van der Wal AC, Becker AE. Atherosclerosis, inflammation, and infection. J Pathol 2000; 190(3):237-243.
25. Jonasson L, Holm J, Skalli O, et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6:131-138.
26. Stemme S, Faber B, Holm J, et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995; 92:3893-3897.
27. Kraiss LW, Raines EW, Wilcox JN, et al. Regional expression of the platelet-derived growth factor and its receptors in a primate graft model of vessel wall assembly. J Clin Invest 1993; 92:338-348.
28. Sharefkin JB, Diamond SL, Eskin SG, et al. Fluid flow decreases preproendothelin mRNA levels and suppresses endothelin-1 peptide release in cultured human endothelial cells. J Vasc Surg 1991; 14:1-9.
29. Rieder MJ, Carmona R, Krieger JE, et al. Suppression of angiotensin-converting enzyme expression and activity by shear stress. Circ Res 1997; 80:312-319.
30. Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991; 17:187-193.
31. Ohno M, Cooke JP, Dzau VJ, Gibbons GH. Fluid shear stress induces endothelial transforming growth factor beta-1 transcription and production. Modulation by potassium channel blockade. J Clin Invest 1995; 95:1363-1369.
32. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12:56-62.
33. Giroud D, Li JM, Urban P, et al. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992; 69:729-732.
34. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78:1157-1166.
35. Nobuyoshi M, Tanaka M, Nosaka H, et al. Progression of coronary atherosclerosis: Is coronary spasm related to progression? J Am Coll Cardiol 1991; 18:904-910.
36. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657-671.
37. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53:363-373.
38. Mann JM, Davies MJ. Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. Circulation 1996; 94:928-931.
39. Falk E. Why do plaques rupture? [review] Circulation 1992; 86(6Suppl):III30-III42.
40. Davies MJ. Stability and instability: Two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94:2013-2020.
41. Felton CV, Crook D, Davies MJ, Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vase Biol 1997; 17:1337-1345.
42. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50:127-134.
43. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2:941-944.
44. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89:36-44.
45. Frink RJ. Chronic ulcerated plaques: New insights into the pathogenesis of acute coronary disease. J Invasive Cardiol 1994; 6:173-185.
46. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol 1989; 63:114E-120E.
47. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid. macrophage, and smooth muscle cell content. Br Heart J 1993; 69:377-381.
48. Wagner WD, St. Clair RW, Clarkson TB, Connor JR. A study of atherosclerosis regression in Macaca mulatta: III. Chemical changes in arteries from animals with atherosclerosis induced for 19 months and regressed for 48 months at plasma cholesterol concentrations of 300 or 200 mg/dL. Am J Pathol 1980; 100:633-650.
49. Loree HM, Tobias BJ, Gibson LJ, et al. Mechanical properties of model atherosclerotic lesion lipid pools. Arterioscler Thromb 1994; 14:230-234.
50. Small DM. George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis 1988; 8:103-129.
51. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995; 146:3-15.
52. Constantinides P. Plaque fissures in human coronary thrombosis. J Atheroscler Res 1966; 6:1-17.
53. Friedman M. The coronary thrombus: Its origin and fate. Hum Pathol 1971; 2:81-128.
54. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 2:1565-1569
55. Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99:2503-2509.
56. Brown DL, Hibbs MS, Kearney M, et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91:2125-2131.
57. Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996; 156:3952-3960.
58. Lee RT, Kamm R. Vascular mechanics for the cardiologist. J Am Coll Cardiol 1994; 23:1289-1295.
59. MacIsaac AI, Thomas JD, Topol EJ. Toward the quiescent coronary plaque. J Am Coll Cardiol 1993; 22:1228-1241.
60. Lin CS, Penha PD, Zak FG, Lin JC. Morphodynamic interpretation of acute coronary thrombosis, with special reference to volcano-like eruption of atheromatous plaque caused by coronary artery spasm. Angiology 1988; 39:535-547.
61. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23:1562-1569.
62. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95:594-599.
63. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 1989; 86:2839-2843.
64. Thiruvikraman SV, Guha A, Roboz J, et al. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors Vila and X. Lab Invest 1996; 75:451-461.
65. Annex BH, Denning SM, Channon KM, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91:619-622.
66. Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90:775-778.
67. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94: 3090-3097.
68. Mallat Z, Hugel B, Ohan J, et al. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: A role for apoptosis in plaque thrombogenicity. Circulation 1999; 99:348-353.
69. Suefuji H, Ogawa H, Yasue H, et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134:253-259.
70. Soejima H, Ogawa H, Yasue H, et al. Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris. Thromb Res 1999; 93:17-25.
71. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci U S A 1999; 96:2311-2315.
72. Badimon L, Martinez-Gonzalez J, Royo T, et al. A sudden increase in plasma epinephrine levels transiently enhances platelet deposition on severely damaged arterial wall. Thrombosis and Haemostasis 1999; 82:1736-1742
73. Spalding A, Vaitkevicius H, Dill S, et al. Mechanism of epinephrine-induced platelet aggregation. Hypertension 1998; 31:603-607.
74. Goto S, Handa S, Takahashi E, et al. Synergistic effect of epinephrine and shearing on platelet activation. Thromb Res 1996; 84:351-359.
75. Krantz DS, Kop WJ, Santiago HT, Gottdiener JS. Mental stress as a trigger of myocardial ischemia and infarction. Cardiol Clin 1996; 14:271-287.
76. Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313:1315-1322.
77. Johnstone MT, Mittleman M, Tofler G, Muller JE. The pathophysiology of the onset of morning cardiovascular events. Am J Hypertens 1996; 9:22S-28S.
78. Willich SN, Linderer T, Wegscheider K, et al. Increased morning incidence of myocardial infarction in the ISAM Study: Absence with prior beta-adrenergic blockade. ISAM Study Group. Circulation 1989; 80:853-855.
79. Winniford MD, Wheelan KR, Kremers MS, et al. Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease: Evidence for adrenergically mediated alterations in coronary artery tone. Circulation 1986; 73:662-667.
80. Fuster V, Chesebro JH, Frye RL, Elveback LR. Platelet survival and the development of coronary artery disease in the young adult: Effects of cigarette smoking, strong family history and medical therapy. Circulation 1981; 63:546-551.
81. Blann AD, Kirkpatrick U, Devine C, et al. The influence of acute smoking on leucocytes, platelets and the endothelium. Atherosclerosis 1998; 141:133-139.
82. Powell JT. Vascular damage from smoking: disease mechanisms at the arterial wall. Vasc Med 1998; 3:21-28.
83. Paul O. Background of the prevention of cardiovascular disease. II. Arteriosclerosis, hypertension, and selected risk factors. Circulation 1989; 80:206-214.
84. Buhler FR, Vesanen K, Watters JT, Bolli P. Impact of smoking on heart attacks, strokes, blood pressure control, drug dose, and quality of life aspects in the International Prospective Primary Prevention Study in Hypertension. Am Heart J 1988; 115:282-288.
85. Hunt BJ. The relation between abnormal hemostatic function and the progression of coronary disease. Curr Opin Cardiol 1990; 5:758-765.
86. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332:635-641.
87. Rauch U, Osende JI, Chesebro JH, et al. Statins and cardiovascular diseases: The multiple effects of lipid-lowering therapy by statins. Atherosclerosis 2000; 153:181-189.
88. Badimon JJ, Badimon L, Turitto VT, Fuster V. Platelet deposition at high shear rates is enhanced by high plasma choleslerol levels. In vivo study in the rabbit model. Arterioscler Thromb 1991; 11:395-402.
89. Carvalho AC, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290:434-438.
90. Henry PD, Cabello OA, Chen CH. Hypercholesterolemia and endothelial dysfunction. Curr Opin Lipidol 1995; 6:190-195.
91. Lacoste L, Lam JY, Hung J, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92:3172-3177.
92. Boers GH. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost 1997; 78:520-522.
93. Boers GH, Smals AG, Trijbels FJ, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313:709-715.
94. de Jong SC, van den Berg M, Rauwerda JA, Stehouwer CD. Hyperhomocysteinemia and atherothrombotic disease. Semin Thromb Hemost 1998; 24:381-385.
95. Prasad K. Homocysteine, a risk factor for cardiovascular disease. Int J Angiology 1999; 8:76-86.
96. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342:1792-1801.
97. Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10:77-82.
98. Geppert A, Graf S, Beckmann R, et al. Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. Arterioscler Thromb Vasc Biol 1998; 18:1634-1642.
99. Thompson SG, Kienast J, Pike SDM, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with unstable angina. N Engl J Med 1995; 332:635-641.
100. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313:1557-1563.
101. Meade TW. Fibrinogen and cardiovascular disease. J Clin Pathol 1997; 50:13-15.
102. Maseri A, L'Abbate A, Baroldi G, et al. Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of "preinfarction" angina. N Engl J Med 1978; 299:1271-1277.
103. Willerson JT, Golino P, Eidt J, et al. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989; 80:198-205.
104. Gasser RN, Dienstl F, Puschendorf B, et al. New perspectives on the function of coronary artery spasm in acute myocardial infarction: the thromboischemic reentry mechanism. A review of 10 years research on the pathophysiology of AMI. Angiology 1986; 37:880-887.
105. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The patho-genesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326:242-250.
106. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326:310-318.
107. Theroux P, Fuster V. Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction. Circulation 1998; 97:1195-1206.
108. de Feyter PJ, Ozaki Y, Baptista J, et al. Ischemia-related lesion characteristics in patients with stable or unstable angina. A study with intracoronary angioscopy and ultrasound. Circulation 1995; 92:1408-1413.
109. Silva JA, Escobar A, Collins TJ, et al. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 1995; 92:1731-1736.
110. Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315:913-919.
111. Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326:287-291.
112. Nesto RW, Waxman S, Mittleman MA, et al. Angioscopy of culprit coronary lesions in unstable angina pectoris and correlation of clinical presentation with plaque morphology. Am J Cardiol 1998; 81:225-228.
113. Van Belle E, Lablanche JM, Bauters C, et al. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: Natural history and the effect of thrombolysis. Circulation 1998; 97:26-33.
114. Uchida Y, Tomaru T, Nakamura F, et al. Percutaneous coronary angioscopy in patients with ischemic heart disease. Am Heart J 1987; 114:1216-1222.
115. Uchida Y, Nakamura F, Tomaru T, et al. Prediction of acute coronary syndromes by percutaneous coronary angioscopy in patients with stable angina. Am Heart J 1995; 130:195-203.
116. Rehr R, Disciascio G, Vetrovec G, Cowley M. Angiographic morphology of coronary artery stenoses in prolonged rest angina: Evidence of intracoronary thrombosis. J Am Coll Cardiol 1989; 14:1429-1437.
117. Braunwald E, Jones RH, Mark DB, et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994; 90:613-622.
118. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. J Am Coll Cardiol 1993; 22:1141-1154.
119. Danchin N. Is myocardial revascularisation for tight coronary stenoses always necessary? Lancet 1993; 342:224-225.
120. Mehta D, Curwin J, Gomes JA, Fuster V. Sudden death in coronary artery disease: Acute ischemia versus myocardial substrate. Circulation 1997; 96:3215-3223.
121. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997; 96:3264-3265.
122. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983; 24:1070-1076.
123. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16:831-842.
124. Khoo JC, Miller E, McLoughlin P, Steinberg D. Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis 1988; 8:348-358.
125. Khoo JC, Miller E, Pio F, et al. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb 1992; 12:1258-1266.
126. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272:20963-20966.
127. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52:223-261.
128. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996; 7:330-335.
129. Slyper AH. Low-density lipoprotein density and atherosclerosis. Unraveling the connection. JAMA 1994; 272:305-308.
130. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992; 93:189-199.
131. de Graaf J, Hak-Lemmers HL, Hectors MP, et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11:298-306.
132. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A 1987; 84:7725-7729.
133. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A 1987; 84:5928-5931.
134. Sasahara M, Raines EW, Chait A. et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 1994; 94:155-164.
135. Chang MY, Sasahara M, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. Arterioscler Thromb Vasc Biol 1995; 15:1631-1640.
136. Reaven PD, Khouw A, Beltz WF, et al. Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene. Arterioscler Thromb 1993; 13:590-600.
137. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342:154-160.
138. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450-1456.
139. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328:1444-1449.
140. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347:781-786.
141. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150-1155.
142. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145-1149.
143. Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis 1996; 121:1-12.
144. Decossin C, Tailleux A, Fruchart JC, Fievet C. Prevention of in vitro low-density lipoprotein oxidation by an albumin-containing Lp A-I subfraction. Biochim Biophys Acta 1995; 1255:31-38.
145. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981; 67:827-837.
146. Ashby DT, Rye KA, Clay MA, et al. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18:1450-1455.
147. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418.
148. Dahlen GH, Guyton JR, Attar M, et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74:758-765.
149. Djurovic S, Berg K. Epidemiology of Lp(a) lipoprotein: Its role in atherosclerotic/thrombotic disease. Clin Genet 1997; 52:281-292.
150. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322:1494-1499.
151. Hopkins PN, Hunt SC, Schreiner PJ, et al. Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: Results from the NHLBI Family Heart Study. Atherosclerosis 1998; 141:333-345.
152. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330:132-137.
153. Scanu AM. Atherothrombogenicity of lipoprotein(a): The debate. Am J Cardiol 1998; 82:26Q-33Q.
154. Allen S, Khan S, Tam S, et al. Expression of adhesion molecules by lp(a): A potential novel mechanism for its atherogenicity. FASEB J 1998; 12:1765-1776.
155. Chappey O, Dosquet C, Wautier MP, Wautier JL. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997; 27:97-108.
156. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997; 126:296-306.
157. Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes 1992; 41 Suppl 2:26-31.
158. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322:1769-1774.
159. McGill JB, Schneider DJ, Arfken CL, et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43:104-109.
160. Badimon JJ, Lettino M, Toschi V, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99:1780-1787.
161. Ridker PM. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks? Ann Intern Med 1999; 130:933-937.